ALBI Grade (Liver)ASTCT Grading ATA Thyroid Risk BCLC 2022 Staging (HCC)BSA (Mosteller)CLL-IPI CML ELTS Score CNS-IPI CTCAE v5.0 Calvert Formula DIPSS-Plus (Myelofibrosis)Deauville Score EAU NMIBC Risk ECOG Performance Status ELN 2022 Risk (AML)ELN CML Milestones FIGO 2021 (Ovarian)FIGO 2023 (Endometrial)FLIPI-2 Fleischner 2017 Guidelines Fong Clinical Risk Score HCT-CI (Sorror Score)HPV/p16 Oropharynx IGCCCG Risk (Testicular)IMDC (Heng) Criteria IMWG Myeloma Frailty IPSS-M (Molecular MDS)ISUP Grade Groups Karnofsky Status (KPS)Khorana Score Lugano Classification Lung-RADS v2022 MIPI-b (Biological)MRD Assessment Framework MSI/MMR Interpretation Mayo 20/2/20 (SMM)NCCN Prostate Risk NCCN-IPI (DLBCL)NSCLC GPA Oncotype DX Recurrence Opioid Equianalgesic PD-L1 TPS Interpretation PERCIST 2.0 PREDICT v3.0 Platinum-Free Interval R2-ISS (Revised 2)RANO 2.0 RCB (Residual Cancer Burden)RECIST 1.1 ROMA Score SAVER Score SINS Score SLiM-CRAB Criteria Sedlis/Peters Criteria TNM 8th (Colorectal)TNM 8th Ed (Prognostic)TNM 9th (Nasopharynx)TNM 9th Ed (NSCLC)TNM 9th Ed (SCLC)Tyrer-Cuzick (IBIS v8)WHO 2021 CNS Class.WHO 2022 / ICC 2022 AML Z0011 Eligibility iRECIST iwCLL 2018 Response mRECIST (HCC)mRENAL Score mrTRG (Rectal MRI)

Recent Journal Updates

DiabetologiaJun 8, 2026

Genetics of MASLD: a diabetes perspective

Clinical Context

We think this might be relevant to the clinical guidance for PD-L1 TPS Interpretation.

DiabetologiaJun 6, 2026

Plasma small RNA profiling reveals a three-miRNA signature associated with early beta cell dysfunction across glucose tolerance stages

Clinical Context

We think this might be relevant to the clinical guidance for PD-L1 TPS Interpretation.

DiabetologiaJun 5, 2026

Early glycaemic exposure and cancer risk in people with newly diagnosed type 2 diabetes

Clinical Context

We think this might be relevant to the clinical guidance for PD-L1 TPS Interpretation.

PD-L1 TPS Interpretation

PD-L1 TPSTumor Proportion Score Interpretation

Pathology Report Data

Tumor Proportion Score (%)

Percent

Clinical Context

The TPS is the percentage of viable tumor cells showing partial or complete membrane staining at any intensity. It is the primary biomarker for Pembrolizumab eligibility in NSCLC.

Expression Tier

High Expressor

Therapeutic Strategy

PD-L1 expression ≥ 50%. High likelihood of response to checkpoint inhibitor monotherapy (e.g., Pembrolizumab) in the first-line setting.

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Clinical Use

Mandatory biomarker testing for all newly diagnosed advanced/metastatic NSCLC.

Used to decide whether a patient can receive immunotherapy alone (monotherapy) or if chemotherapy must be combined with immunotherapy.

Unlike the CPS (Combined Positive Score) used in gastric or head/neck cancers, TPS evaluates ONLY the tumor cells.

Related Scores in Practice

In clinical practice, this assessment is frequently evaluated alongside other validated measures. Depending on the patient's presentation and specific diagnostic requirements, you may also need to utilize the TNM 9th Ed (NSCLC), NSCLC GPA or the MSI/MMR Interpretation to formulate a comprehensive care plan.

Last Comprehensive Review: 2026